QT Prolongation in Cancer Patients

Background: QT prolongation and torsades de pointes pose a major concern for cardiologists and oncologists. Although cancer patients are suspected to have prolonged QT intervals, this has not been investigated in a large population. The purpose of this study was to analyze the QT interval distributi...

Full description

Bibliographic Details
Main Authors: Peter Kim, Luke Masha, Amanda Olson, Cezar Iliescu, Kaveh Karimzad, Saamir Hassan, Nicolas Palaskas, Jean-Bernard Durand, Cheuk Hong Leung, Juan Lopez-Mattei
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
ECG
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.613625/full
id doaj-6b3cd8531285480aa38013df5d9f778e
record_format Article
spelling doaj-6b3cd8531285480aa38013df5d9f778e2021-02-25T04:41:48ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-02-01810.3389/fcvm.2021.613625613625QT Prolongation in Cancer PatientsPeter Kim0Luke Masha1Luke Masha2Amanda Olson3Cezar Iliescu4Kaveh Karimzad5Saamir Hassan6Nicolas Palaskas7Jean-Bernard Durand8Cheuk Hong Leung9Juan Lopez-Mattei10Division of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Cardiology, Oregon Health and Science University, Portland, OR, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDivision of Internal Medicine, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesBackground: QT prolongation and torsades de pointes pose a major concern for cardiologists and oncologists. Although cancer patients are suspected to have prolonged QT intervals, this has not been investigated in a large population. The purpose of this study was to analyze the QT interval distribution in a cancer population and compare it to a non-cancer population in the same institution.Methods: The study was a retrospective review of 82,410 ECGs performed in cancer patients (51.8% women and 48.2% men) and 775 ECGs performed in normal stem cell donors (47.9% women and 52.1% men) from January 2009 to December 2013 at the University of Texas MD Anderson Cancer Center. Pharmacy prescription data was also collected and analyzed during the same time period. Correction of the QT interval for the heart rate was performed using the Bazett and Fridericia formulas.Results: After QT correction for heart rate by the Fridericia formula (QTcF), the mean and 99% percentile QTc for cancer patients were 414 and 473 ms, respectively. These were significantly longer than the normal stem cell donors, 407 and 458 ms, p < 0.001, respectively. Among the cancer patients, the QTc was longer in the inpatient setting when compared to both outpatient and emergency center areas. The most commonly prescribed QT prolonging medications identified were ondansetron and methadone.Conclusion: Our study demonstrates significantly longer QTc intervals in cancer patients, especially in the inpatient setting. Frequently prescribed QT prolonging medications such as antiemetics and analgesics may have a causative role in QT prolongation seen in our cancer hospital.https://www.frontiersin.org/articles/10.3389/fcvm.2021.613625/fullQT prolongationcardiooncologyECGtorsades de pointescardiac monitoring in clinical trials
collection DOAJ
language English
format Article
sources DOAJ
author Peter Kim
Luke Masha
Luke Masha
Amanda Olson
Cezar Iliescu
Kaveh Karimzad
Saamir Hassan
Nicolas Palaskas
Jean-Bernard Durand
Cheuk Hong Leung
Juan Lopez-Mattei
spellingShingle Peter Kim
Luke Masha
Luke Masha
Amanda Olson
Cezar Iliescu
Kaveh Karimzad
Saamir Hassan
Nicolas Palaskas
Jean-Bernard Durand
Cheuk Hong Leung
Juan Lopez-Mattei
QT Prolongation in Cancer Patients
Frontiers in Cardiovascular Medicine
QT prolongation
cardiooncology
ECG
torsades de pointes
cardiac monitoring in clinical trials
author_facet Peter Kim
Luke Masha
Luke Masha
Amanda Olson
Cezar Iliescu
Kaveh Karimzad
Saamir Hassan
Nicolas Palaskas
Jean-Bernard Durand
Cheuk Hong Leung
Juan Lopez-Mattei
author_sort Peter Kim
title QT Prolongation in Cancer Patients
title_short QT Prolongation in Cancer Patients
title_full QT Prolongation in Cancer Patients
title_fullStr QT Prolongation in Cancer Patients
title_full_unstemmed QT Prolongation in Cancer Patients
title_sort qt prolongation in cancer patients
publisher Frontiers Media S.A.
series Frontiers in Cardiovascular Medicine
issn 2297-055X
publishDate 2021-02-01
description Background: QT prolongation and torsades de pointes pose a major concern for cardiologists and oncologists. Although cancer patients are suspected to have prolonged QT intervals, this has not been investigated in a large population. The purpose of this study was to analyze the QT interval distribution in a cancer population and compare it to a non-cancer population in the same institution.Methods: The study was a retrospective review of 82,410 ECGs performed in cancer patients (51.8% women and 48.2% men) and 775 ECGs performed in normal stem cell donors (47.9% women and 52.1% men) from January 2009 to December 2013 at the University of Texas MD Anderson Cancer Center. Pharmacy prescription data was also collected and analyzed during the same time period. Correction of the QT interval for the heart rate was performed using the Bazett and Fridericia formulas.Results: After QT correction for heart rate by the Fridericia formula (QTcF), the mean and 99% percentile QTc for cancer patients were 414 and 473 ms, respectively. These were significantly longer than the normal stem cell donors, 407 and 458 ms, p < 0.001, respectively. Among the cancer patients, the QTc was longer in the inpatient setting when compared to both outpatient and emergency center areas. The most commonly prescribed QT prolonging medications identified were ondansetron and methadone.Conclusion: Our study demonstrates significantly longer QTc intervals in cancer patients, especially in the inpatient setting. Frequently prescribed QT prolonging medications such as antiemetics and analgesics may have a causative role in QT prolongation seen in our cancer hospital.
topic QT prolongation
cardiooncology
ECG
torsades de pointes
cardiac monitoring in clinical trials
url https://www.frontiersin.org/articles/10.3389/fcvm.2021.613625/full
work_keys_str_mv AT peterkim qtprolongationincancerpatients
AT lukemasha qtprolongationincancerpatients
AT lukemasha qtprolongationincancerpatients
AT amandaolson qtprolongationincancerpatients
AT cezariliescu qtprolongationincancerpatients
AT kavehkarimzad qtprolongationincancerpatients
AT saamirhassan qtprolongationincancerpatients
AT nicolaspalaskas qtprolongationincancerpatients
AT jeanbernarddurand qtprolongationincancerpatients
AT cheukhongleung qtprolongationincancerpatients
AT juanlopezmattei qtprolongationincancerpatients
_version_ 1724252079876210688